SCHEMBL13221085

SCHEMBL13221085

CC(=O)Nc1ccc(-c2cc3nccn3c(Nc3cc(C4CC4)[nH]n3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.51
▸ IGF1R P08069 7/20 0.50
▸ USP30 Q70CQ3 1/20 0.48
▸ AURKB Q96GD4 2/20 0.47
▸ GSK3B P49841 1/20 0.47
▸ FYN P06241 1/20 0.41
▸ TNIK Q9UKE5 1/20 0.41
▸ SYK P43405 2/20 0.41
▸ CDK7 P50613 1/20 0.41
▸ CDK13 Q14004 1/20 0.41
▸ PAK1 Q13153 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ INSR P06213 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ LYN P07948 1/20 0.40
▸ RET P07949 1/20 0.40
▸ ROS1 P08922 1/20 0.40
▸ FER P16591 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221320 0.86 SRC (0.48) SRCIGF1RAURKBGSK3BPAK1
SCHEMBL13221031 0.86 PAK1 (0.44) IGF1RSYKPAK1
SCHEMBL13221056 0.84 NEK1 (0.47) IGF1RPAK1CDK2
SCHEMBL13220997 0.84 NEK1 (0.49) IGF1RPAK1
SCHEMBL13221032 0.83 IGF1R (0.52) SRCIGF1RAURKBSYKPAK1
SCHEMBL13221095 0.83 IGF1R (0.53) IGF1RSYKPAK1
SCHEMBL3046927 0.82 SRC (0.42) SRCIGF1RAURKBSYKPAK1
SCHEMBL13221028 0.82 IGF1R (0.45) IGF1RSYKPAK1
SCHEMBL13221080 0.82 MAP4K2 (0.47) SRCIGF1RAURKBGSK3BSYK
SCHEMBL13221069 0.82 CDK2 (0.44) SRCIGF1RAURKBGSK3BSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 SRC 63/4885IGF1R 787/4885USP30 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback